{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:18Z","timestamp":1786982118165,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11886-017-0926-y","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T03:55:52Z","timestamp":1507780552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Innovations in Drug-Eluting Stents for Peripheral Arterial Disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Roi","family":"Altit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"926_CR1","unstructured":"American Heart Association. Heart Disease and Stroke Statistics\u20142004. 2004; Dallas."},{"issue":"11","key":"926_CR2","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1161\/01.CIR.94.11.3026","volume":"94","author":"JI Weitz","year":"1996","unstructured":"Weitz JI, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94(11):3026\u201349.","journal-title":"Circulation"},{"key":"926_CR3","doi-asserted-by":"publisher","unstructured":"Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. J Am Coll Cardiol. 2016;67(11):1338\u201357. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2015.12.049\n\n.","DOI":"10.1016\/j.jacc.2015.12.049"},{"key":"926_CR4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/CIRCULATIONAHA.114.009867","volume":"130","author":"J Nordanstig","year":"2014","unstructured":"Nordanstig J, Taft C, Hensater M, Perlander A, Osterberg K, Jivegard L. Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the invasive revascularization or not in intermittent claudication (IRONIC) trial. Circulation. 2014;130:939\u201347.","journal-title":"Circulation"},{"issue":"4","key":"926_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/157340309789317823","volume":"5","author":"C Kasapis","year":"2009","unstructured":"Kasapis C, Gurm HS. Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. Curr Cardiol Rev. 2009;5(4):296\u2013311. \nhttps:\/\/doi.org\/10.2174\/157340309789317823\n\n.","journal-title":"Curr Cardiol Rev"},{"issue":"19","key":"926_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.jacc.2011.08.023","volume":"58","author":"TW Rooke","year":"2011","unstructured":"Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF\/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;58(19):2020\u201345. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2011.08.023\n\n.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"926_CR7","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","volume":"69","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC guideline on the Management of Patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):e71\u2013e126.","journal-title":"J Am Coll Cardiol"},{"key":"926_CR8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ccd.21104","volume":"69","author":"KJ Rocha-Singh","year":"2007","unstructured":"Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"926_CR9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/CIRCULATIONAHA.107.689141","volume":"116","author":"H Krankenberg","year":"2007","unstructured":"Krankenberg H, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length the femoral artery stenting trial (FAST). Circulation. 2007;116(3):285\u201392.","journal-title":"Circulation"},{"key":"926_CR10","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jacc.2013.05.079","volume":"62.15","author":"J Lammer","year":"2013","unstructured":"Lammer J, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62.15:1320\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"926_CR11","first-page":"E76","volume":"11","author":"BS Weinstock","year":"2014","unstructured":"Weinstock BS. Covered stents in the treatment of superficial femoral artery disease. Vasc Dis Manag. 2014;11(4):E76\u201386.","journal-title":"Vasc Dis Manag"},{"issue":"6","key":"926_CR12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1583\/05-1704.1","volume":"13","author":"SH Duda","year":"2006","unstructured":"Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13(6):701\u201310.","journal-title":"J Endovasc Ther"},{"key":"926_CR13","unstructured":"Lammer J. First-in-human clinical trial of nitinol self-expanding everolimus-eluting stent for prevention of restenosis following infrainguinal endovascular intervention: the STRIDES trial. Presented at Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting, Lisbon, Portugal, 2009."},{"key":"926_CR14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","volume":"4.5","author":"MD Dake","year":"2011","unstructured":"\u2022\u2022 Dake MD, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4.5:495\u2013504. This trial very eloquently demonstrated the superiority of drug-eluting stents over PTA and BMS technology and was a landmark trial within the realm of PAD.","journal-title":"Circ Cardiovasc Interv"},{"key":"926_CR15","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","volume":"133.15","author":"MD Dake","year":"2016","unstructured":"\u2022 Dake MD, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133.15:1472\u201383. This follow-up analysis proved the sustainability of DES technology at limiting restenosis.","journal-title":"Circulation"},{"issue":"4","key":"926_CR16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ccd.23064","volume":"78","author":"O Iida","year":"2011","unstructured":"Iida O, Uematsu M, Soga Y, Hirano K, Suzuki K, Yokoi H, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses. Catheter Cardiovasc Interv. 2011;78(4):611\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"926_CR17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/1526602816641669","volume":"23","author":"K Miki","year":"2016","unstructured":"Miki K, Fujii K, Kawasaki D, Shibuya M, Fukunaga M, Imanaka T, et al. Intravascular ultrasound-derived stent dimensions as predictors of angiographic restenosis following nitinol stent implantation in the superficial femoral artery. J Endovasc Ther. 2016;23(3):424\u201332.","journal-title":"J Endovasc Ther"},{"issue":"5","key":"926_CR18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/1526602816650206","volume":"23","author":"S M\u00fcller-H\u00fclsbeck","year":"2016","unstructured":"\u2022 M\u00fcller-H\u00fclsbeck S, et al. Twelve-month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23(5):701\u20137. This trial reported the highest vessel patency rate within the PAD literature to date.","journal-title":"J Endovasc Ther"},{"key":"926_CR19","unstructured":"Muller-Hulsbeck S. Drug-eluting stents\u2014new developments and established data. Presented at CIRSE; 2016. Barcelona Spain September 10\u201314, 2016."},{"key":"926_CR20","unstructured":"Boston Scientific Corporation; Marlborough, MA. ELUVIA drug-eluting stent versus Zilver PTX stent (IMPERIAL). In: \nClinicalTrials.gov\n\n [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Nov 4]. Available from: \nclinicaltrials.gov\/ct2\/show\/NCT02574481\n\n NLM Identifier: NCT02574481."},{"issue":"22","key":"926_CR21","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2012.08.989","volume":"60","author":"D Scheinert","year":"2012","unstructured":"Scheinert D, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60(22):2290\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"926_CR22","doi-asserted-by":"crossref","unstructured":"Rastan A et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011; ehr144.","DOI":"10.1093\/eurheartj\/ehr144"},{"key":"926_CR23","doi-asserted-by":"crossref","unstructured":"Rastan A, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60(7):587\u201391.","DOI":"10.1016\/j.jacc.2012.04.035"},{"issue":"2","key":"926_CR24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jvs.2011.07.099","volume":"55","author":"M Bosiers","year":"2012","unstructured":"Bosiers M, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55(2):390\u20138.","journal-title":"J Vasc Surg"},{"key":"926_CR25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jcin.2016.02.051","volume":"9","author":"J Lammer","year":"2016","unstructured":"Lammer J, Bosiers M, Deloose K, et al. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv. 2016;9:1178\u201387.","journal-title":"JACC Cardiovasc Interv"},{"key":"926_CR26","doi-asserted-by":"crossref","unstructured":"Varcoe RL, et al. Experience with the absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee: 12-month clinical and imaging outcomes. J Am Coll Cardiol Intv. 2016;9(16):1721\u20138.","DOI":"10.1016\/j.jcin.2016.06.005"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0926-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T02:03:33Z","timestamp":1508810613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0926-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0926-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]},"article-number":"117"}}